Alkem Laboratories Q2 FY27 Earnings Call: Guides 11% India Growth, Holds 20-21% Margin Guidance

Steady Top Line, Bottom Line Under Pressure

• Revenue of Rs.4,520 crore, +13.8% YoY — Q2 FY 2026-2027 growth was at par with the Indian pharmaceutical industry's 13.8% per IQVIA; EBITDA came in at Rs.1,025 crore with margin of 22.5%, up 11.3% YoY.
• Net profit declined 11.7% YoY — PBT grew 7.7% YoY in Q2 FY 2026-2027; below-EBITDA items include Occlutech PPA depreciation of Rs.28 crore booked in Q2, which will continue in subsequent quarters, plus interest on Occlutech borrowing (per Deputy CFO Dishant Doshi).
• Chronic outperformance of 640bps — per IQVIA Q2 FY 2026-2027, chronic grew 22.4% vs industry's 16%, while acute grew 12.1% vs IPM's 12.3%; Alkem outperformed the IPM in 8 key focus therapies (derma 1.6x, pain 1.5x, anti-diabetic 1.5x, respiratory 1.5x).
• Newer platforms remain small and volatile — Q2 FY 2026-2027 biotech sales of Rs.70 crore (down 35% YoY on lumpy CDMO business) and medtech sales of Rs.133 crore, with Occlutech consolidated from Q2 FY 2026-2027 (consolidation began 16 July, 2.5 months of the quarter).
• R&D at 4.3% of revenues — FY 2026-2027 guidance maintained at 4-4.5% of revenue; spend is lumpy, with RLD orders placed in Q2 FY 2026-2027 driving the YoY/QoQ jump and Q4 typically the heaviest quarter.
• Regulatory mixed bag — Daman facility remediation is progressing with the company engaged with the USFDA on its OAI status; separately, the USFDA inspection of the Mandwa API facility concluded with no 483s.

At Par With IPM; Trade Generics the Drag

• FY 2026-2027 India growth guided at ~11% — MD Sandeep Singh expects this, above the analyst's suggested 9-10% range; branded business is performing at par with the market while medtech, trade generics, and biosimilars drag overall growth.
• Trade generics slowdown has two causes — rising competitive intensity (all big players have entered a segment that earlier had few players) and Alkem's own tightened credit policies; with Alkem the biggest or neck-and-neck with Cipla, sustaining historic double-digit growth on the large base is challenging; management expects better growth in H2 FY 2026-2027 and is entering animal generics (early days, outcome uncertain).
• IQVIA comparison caveat — total India business was only in line with IPM because IQVIA does not cover trade generics; the comparison is of the whole India business against the IQVIA-covered branded business only.
• Chronic is the new CEO's top priority — CEO Amrut Naik noted Alkem's chronic share stands at 24-25% per IQVIA as of Q2 FY 2026-2027 versus the industry at about 65:35 (acute:chronic); management intends to become materially larger in chronic, where growth is already running ahead of the IPM.
• Semaglutide execution proof point — over the past six months (≈ H1 FY 2026-2027) the team gained significant share amid cut-throat competition, with the CEO referencing Sandeep Singh's remark that Alkem is now No. 1 in volume; BMN is No. 1 per the latest reported QEA data; focus therapies also include cardiovascular, neuropsychiatry, derma, respiratory, and vitamins/minerals/nutrition.
• New CEO roadmap pending — Amrut Naik (joined effective 11 Nov 2026, ~27 years' experience) said he is "still learning the ropes" and expects a clearer 3-5 year India strategic direction in 3-4 months (≈ Q4 FY 2026-2027).

Daman OAI Overhang Caps US Trajectory

• FY 2026-2027 US growth guided at mid-single digit CC — H2 FY 2026-2027 expected slightly better than H1 actuals, but management expects H2 to remain challenging despite more launches expected.
• Q2 FY 2026-2027 US contracted 3% CC — ~10% volume expansion was offset by ~16% price erosion, partially compensated by ~3% from new launches; favorable currency lifted reported growth to 2%. The 16% price erosion was driven by a single product (Sakiwal), not portfolio-wide; the impact is now in the base.
• 23 ANDAs pending and 18 tentative approvals — as of Q2 FY 2026-2027; around 8 products due for launch over the next 6-12 months (spanning into FY 2027-2028) were filed from Daman — flagged by Deputy CFO Dishant Doshi as the key concern the company is trying to resolve.
• Daman remediation is the "topmost priority" — CEO Amrut Naik committed to resolution "in an expeditious manner"; approvals for 3 important US-launch products are delayed; all remediation responses are submitted and the company awaits the FDA's counter-response on the re-audit. No significant remediation cost in H1 FY 2026-2027 — gaps were procedural, not infrastructural.
• Tolvaptan ramp is slow under REMS — launched in the US in September (Q2 FY 2026-2027), sold only through selected outlets and pharmacies; Sandeep Singh cautioned it will not be close to Lupin's numbers, asked investors to assess by Q3 FY 2026-2027, and noted it is not anywhere close to a meaningful contribution currently.
• Denosumab biosimilar US approval delayed — due to analytical/regulatory queries (explicitly not infrastructure issues); management will refile "very soon" after redoing certain analytical methods, with no specific approval timeline provided. Xgeva biosimilar has EU approval but launch awaits a commercial partner (Teramex ruled out, as it focuses on women's healthcare); management sees the EU opportunity as not very meaningful — it "doesn't move the needle too much."

Non-US Momentum Offsets US Softness

• International grew 22.3% in Q2 FY 2026-2027 — US up 2% reported, non-US up 58% (reported growth aided by Occlutech integration); non-US (ex-Occlutech) grew 31% in H1 FY 2026-2027.
• FY 2026-2027 non-US growth guided at mid-teens to higher teens — weighted-average basis, with strong double-digit growth expected in H2 FY 2026-2027; Chile and Australia are the strongest markets, Germany and the UK picking up well, and Colombia and Mexico were the highlight of Q2 FY 2026-2027 with momentum expected through Q3 and Q4 FY 2026-2027.
• FY 2027-2028 international growth guided at mid-teens — management expects the absolute growth delta to be much larger off the higher FY 2026-2027 base, supported by filings across multiple markets and aggressive ramp-up of the developed-market strategy in Europe and the emerging-market strategy.
• Only two US launches in Q1 FY 2026-2027 — dapagliflozin and the dapagliflozin-metformin combination have seen suboptimal uptake versus expectations; no new launches occurred in Q2 FY 2026-2027 due to the OAI status, which does not impact inline products but does impact new approvals.

Enzene Pivots to CDMO; Occlutech Story Intact

• Enzene repositioned primarily as a CDMO — Sandeep Singh said the biosimilar pipeline "will not be that important" for Enzene going forward; client details cannot be disclosed but the opportunity funnel "seems good"; the business will take 2-3 years to mature, and management expects Enzene revenue to double in 4 years with EBITDA break-even within 1.5-2 years (maximum).
• Denosumab BLA setback is the "single biggest disappointment" — Sandeep Singh flagged that 11 players are now in the race, which "would certainly hurt"; the US CDMO ramp is slower than envisioned and India biosimilars B2B price erosion is running slightly ahead of expectations. CEO Amrut Naik said the BLA issue will have no repercussions on other products or customers — differentiation was on analytical methods, with nothing to do with infrastructure or data integrity.
• US CDMO milestone pending — USFDA has inspected the US facility, but until the BLA is approved the status remains a "gray area"; US site approval plus BLA approval is the key milestone, though management maintains the US facility is an advantage and expects customers to come eventually. The US enzyme plant is not fully idle — H2 FY 2026-2027 is expected far busier than H1, and management cautioned against annualizing Q2 FY 2026-2027 losses (multiplying by 4).
• Occlutech outlook intact — Amrut Naik said it is too early to change the outlook 2-3 months after the acquisition; gross margins are 80%, with the big delta expected from the US (current presence insignificant) where product launches are expected in 2028 — a "two-year game." Balance sheet: identifiable intangibles of close to Rs.1,100 crore to be amortized over 10 years, plus goodwill of close to Rs.700 crore.
• Capex of ~Rs.600-700 crore over the next 3-4 years — Enzene requires Rs.300-350 crore over FY 2027-2028 through FY 2029-2030 (beyond which its capex cycle is "more or less done"); MedTech requires ~Rs.400 crore over FY 2027-2028 through FY 2029-2030/FY 2030-2031; MedTech revenue is targeted to reach 3x current levels in 5-6 years, with its EBITDA break-even timing (period unspecified).

Guidance Held Despite H1 Upside; Headwinds Flagged

• FY 2026-2027 EBITDA margin guidance held at 20-21% — management declined to raise it despite H1 FY 2026-2027 tracking comfortably above the higher end; Sandeep Singh cited Occlutech diluting margin by 80bps in Q2 FY 2026-2027 and uncertain Enzene ramp pace as making an upward revision premature.
• Base business margins above 23% in Q2 FY 2026-2027 — Occlutech EBITDA drag was ~80bps with Enzene an additional impact (~100bps referenced); core pharma EBITDA was close to 26%, but management cautioned Q2 is seasonally the strongest quarter and should not be taken as a run-rate.
• FY 2026-2027 consolidated margin may close at best on par with FY 2025-2026's 20.4% — Q3 and Q4 FY 2026-2027 may see margin pressure from the biosimilars and medtech businesses, despite margins currently running a little higher; the ~100bps YoY improvement in reported EBITDA margins is management's aspiration, dependent on multiple factors.
• ~50bps EBITDA margin improvement per year expected from FY 2027-2028 onwards — Sandeep Singh added "hopefully more than that," citing meaningful operational leverage, domestic growth ahead of the IPM, and significantly better international growth; management also expects Enzene and Occlutech to break even in ~18 months (≈ exit FY 2027-2028) and asked investors to factor in roughly a year and a half before the ~50bps drag fades, stating it would "rather trade growth for breaking even."
• MIP headwind lands in H2 FY 2026-2027 — the government-imposed minimum import price on penicillin (and amoxicillin + clavulanic acid) has not fully flowed through the H1 FY 2026-2027 base due to old inventory; the full impact is expected in H2 FY 2026-2027 and is already baked into EBITDA margin guidance. Management also flagged a coming geopolitical situation, beyond biotech and medtech, as a headwind.